Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and Why. | Canada Hyperbarics Skip to main content
Review Current fungal infection reports 2022

Pathogenesis and Pathology of COVID-Associated Mucormycosis: What Is New and Why.

Radotra B, Challa S — Current fungal infection reports, 2022

Tier 2, Indexed

Automatically imported from PubMed based on relevance criteria.

Summary

What Researchers Did

Researchers reviewed the complex interplay of factors contributing to the pathogenesis and pathology of COVID-associated mucormycosis (CAM).

What They Found

They found a sudden increase in COVID-associated mucormycosis (CAM), especially in India during the second wave of the pandemic, driven by factors like hyperglycemia, acidosis, and lowered host defenses. The review highlighted the high background prevalence of diabetes mellitus in India, which, combined with COVID-19 itself and corticosteroid use, contributes to hyperglycemia and increased susceptibility.

Canadian Relevance

This review does not have a direct Canadian connection, as it primarily focuses on the surge of COVID-associated mucormycosis observed in India.

Study Limitations

As a review article, this study synthesizes existing literature and does not present new primary research data or specific patient outcomes.

This plain-language summary is generated with AI assistance and checked against the source abstract before publication. See our editorial policy.

Was this summary helpful?

Study Details

Study Type Review
Category Neurological
Source Pubmed
PubMed ID 36193101
Year Published 2022
Journal Current fungal infection reports

Cite This Study

Share
Discuss with a qualified healthcare professional. Then: Review Coverage Guide View Recognised Conditions

Disclaimer: This study summary is provided for informational and educational purposes only. It does not constitute medical advice. The information presented reflects the findings of the original research authors and may not represent the views of Canada Hyperbarics. Always consult a qualified healthcare professional before making treatment decisions.

Last reviewed: April 2, 2026 | Reviewed by: Canada Hyperbarics Editorial Team | Editorial process | Research sources | Counts & methodology